Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Milk who wrote (293)	6/25/1998 12:38:00 AM
From: CCD	Read Replies (1) \| Respond to of 369

Which first? NASD Delisting or FDA Approval? How long after a company is disqualified for listing is the company actually delisted. Last week, URMD notified investors that the company currently does not meet NASD minimum requirements. If delisting occurs, it is going to take alot of seeds to support URMD's stock price.

To: Milk who wrote (293)	7/16/1998 9:48:00 AM
From: Milk	Read Replies (1) \| Respond to of 369

UroMed Corporation Announces Second-Quarter Results: biz.yahoo.com NEEDHAM, Mass., July 16 /PRNewswire/ -- UroMed Corporation (Nasdaq: URMD - news) today reported revenues of $0.12 million for the second quarter ended June 30, 1998, compared with $0.2 million for the same period of 1997. UroMed reported a second-quarter 1998 net loss of $4.6 million, or $0.85 per share, compared with a net loss of $9.3 million, or $1.75 per share, for the comparable period of 1997. The company ended the second quarter of 1998 with cash, cash equivalents and short-term investments totaling $53.3 million. For the six months ended June 30, 1998, UroMed reported revenues of $0.18 million, compared with revenues of $0.42 million for the same period a year ago. Net loss for the first six months of 1998 was $11.7 million, or $2.17 per share, compared with $17.6 million, or $3.32 per share for the same period in the prior year. ...